Latest News
CMS Confirms Government-to-Government Receipt of Tribal Real-World Evidence Submission for Rampart™ DL Matrix
The Centers for Medicare & Medicaid Services has issued formal Government-to-Government receipt confirmation for the Tribal Biotechnology & Health Consortium’s post-market clinical validation evidence submission on Rampart™ DL Matrix (Q4347), submitted under...
Tribal Consortium Commences Sovereign Enforcement Activity to Protect Tribal Authority Over the Rampart™ Product Line
Following the formal federal identification of Rampart™ DL Matrix (Q4347) as a tribally owned product in the December 15, 2025 CMS Federal Register publication, Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology &...
CMS Federal Register Identifies Rampart™ DL Matrix as Tribally Owned in CY 2026 Medicare Physician Fee Schedule Policy Update
The Centers for Medicare & Medicaid Services today published its CY 2026 Medicare Physician Fee Schedule Policy Update in the Federal Register, formally identifying Rampart™ DL Matrix (HCPCS Q4347) as a tribally owned product in the federal record of covered skin...
Tribal Consortium Issues Sovereign Notice to CMS Requesting Formal Recognition of Tribal Ownership of Q4347
The Tribal Biotechnology & Health Consortium today transmitted a formal Sovereign Notice to the Centers for Medicare & Medicaid Services, accompanied by an ECHAGA Corporation Board Resolution, requesting that CMS formally recognize the tribal ownership of...
CMS Coverage and Analysis Group Confirms Receipt of Tribal Real-World Evidence Submission
The Centers for Medicare & Medicaid Services Coverage and Analysis Group today confirmed receipt of the Tribal Biotechnology & Health Consortium’s post-market clinical validation submission for Rampart™ DL Matrix (Q4347) and confirmed it had forwarded the...
Tribal Consortium Submits Post-Market Clinical Validation of Rampart™ DL Matrix to CMS as Government-to-Government Evidence
The Tribal Biotechnology & Health Consortium today submitted the completed post-market clinical validation of Rampart™ DL Matrix (Q4347) to the Centers for Medicare & Medicaid Services and all seven Medicare Administrative Contractors as a formal sovereign...
A Statement on the Integrity of the Rampart™ Name and the Sovereign Authority of the Tribal Consortium
A STATEMENT FROM THE OFFICE OF THE CEO Issued by Clear Health Pass Holdings, LLC, as Authorized Tribal Agent It has come to the attention of Clear Health Pass Holdings, in its capacity as Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium,...
Rampart™ DL Matrix Issued on CMS Q4 2025 Average Sales Price File for Medicare Part B — 482 Days After Initial Sovereign Consultation
The Centers for Medicare & Medicaid Services has issued Rampart™ DL Matrix (HCPCS Q4347), the only FDA-cleared tribally owned skin substitute in the Medicare system, on the Q4 2025 Average Sales Price file for Medicare Part B. The Q4 2025 ASP rate took effect for...
Tribal Consortium G2G Submission Posted Publicly on Regulations.gov
The Tribal Biotechnology & Health Consortium’s full sovereign submission on the CY 2026 Medicare Physician Fee Schedule has been posted publicly on Regulations.gov, the federal government’s official rulemaking record platform, under Comment ID CMS-2025-0304-13291....
Tribal Consortium Files Comment on CY 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P)
The Tribal Biotechnology & Health Consortium today filed its formal sovereign comment on the proposed CY 2026 Medicare Physician Fee Schedule (CMS-1832-P), continuing a coordinated, multi-docket engagement with the Centers for Medicare & Medicaid Services. The...
Tribal Consortium Files Formal Comment on CY 2026 OPPS/ASC Proposed Rule (CMS-1834-P)
The Tribal Biotechnology & Health Consortium today filed its formal comment on the proposed CY 2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgical Center Payment System rule (CMS-1834-P), addressing the proposed treatment of skin substitute...
Clear Health Pass Appoints Dr. David Burke, MD, MA as Principal Investigator for Post-Market Clinical Validation of Rampart™ DL Matrix
Clear Health Pass Holdings, on behalf of the Tribal Biotechnology & Health Consortium, today announced the appointment of David Burke, MD, MA as Principal Investigator for the post-market clinical validation of Rampart™ DL Matrix (Q4347). Dr. Burke is Department...
Tribal Consortium Files 910-Page Substantive Comment on CY 2026 Medicare Physician Fee Schedule Proposed Rule
The Tribal Biotechnology & Health Consortium today filed a 910-page substantive comment with the Centers for Medicare & Medicaid Services on the proposed CY 2026 Medicare Physician Fee Schedule. The filing, docketed at Regulations.gov as Comment ID...
Clear Health Pass and CMS Coverage Group Convene Working Session on ASP and HCPCS Code Integrity for Q4347
The Tribal Consortium’s Authorized Tribal Agent, Clear Health Pass Holdings, joined a working session with CMS Drug Pricing and the Coverage and Analysis Group to address the Average Sales Price submission and HCPCS code record for Rampart™ DL Matrix (Q4347). The...
CMS Convenes Tribal Consultative Meeting on Rampart™ DL Matrix with Clear Health Pass and the Division of Tribal Affairs
The Centers for Medicare & Medicaid Services convened a formal Tribal Consultative Meeting with Clear Health Pass Holdings, Authorized Tribal Agent for the Tribal Biotechnology & Health Consortium, to review the federal coverage and reimbursement framework for...